GASTROGRAFIN

Dose: 90 to 180 mL
Single Dose: 140 (135)
Frequency: As recommended.
Route: PO
Instructions: 90-180 mL of a 25 to 40 percent solution.

Sodium Diatrizoate also known as Amidotrizoate, Amidotrizoate, Amidotrizoate, Amidotrizoate. . It is of Synthetic origin and belongs to Methylglucamine sodium. . The Molecular Weight of Sodium Diatrizoate is 635.90.

Sodium Diatrizoate is contraindicated in conditions like Asthma,Phaeochromocytoma,Myeloma,Sickle cell disease,Renal impairment.

The severe or irreversible adverse effects of Sodium Diatrizoate, which give rise to further complications include Tachycardia, Pancreatitis, Bradycardia, Renal impairment.Sodium Diatrizoate produces potentially life-threatening effects which include Pulmonary edema, Cardiac arrhythmia, Bronchospasm, Angioneurotic edema, Anaphylactic reactions, Hypertensive crises. which are responsible for the discontinuation of Sodium Diatrizoate therapy.The symptomatic adverse reactions produced by Sodium Diatrizoate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Weakness, Dizziness, Headache, Nausea, Vomiting, Sweating, Flushing, Faintness, Taste disturbances, Metallic taste, Sensation of warmth.

Sodium Diatrizoate is primarily indicated in conditions like Angiography, Arthrography, CT enhancement, Excretion urography, Splenoportography, Venography.

Sodium Diatrizoate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementFamotidineShould not be use concurrently without informing doctor.LansoprazoleShould not be use concurrently without informing doctor.OmeprazoleShould not be use concurrently without informing doctor.RanitidineShould not be use concurrently without informing doctor.Sodium IpodateRisk of renal toxicity may be increased when administration of Sodium Ipodate is followed by Sodium Diatrizoate, especially in patients with hepatic or biliary function impairment.Technetium Tc-99m OxidronatePossible renal and hepatic uptake if diatrizoate sodium is administered intravenously immediately after technetium Tc 99m oxidronate. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, and patients suffering from Liver Malfunction.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Soln Store Below 25°C. Protect from Sunlight.

It should be used with caution in patients with previous reaction to diatrizoates or any other iodinated contrast agent and patient with allergies to other drugs. Diatrizoate should be administered with great caution in patients with asthma and history of allergy, and should be avoided to patients with known hypersensitivity to iodine or contrast media. An IV injection of 0.5 to 1 ml of contrast media has been given as a test for sensitivity before administration of main dose. Caution is needed in patients with severe hepatic (liver) or renal impairment or who may be at a risk of renal failure. Dehydration patients should have their fluid and electrolyte balance corrected before administration of contrast medium. It should be used with extreme caution in patients with hypertension, cardiac disease, phaeochromocytoma, sickle-cell anemia or hypothyroidism. Avoid use during pregnancy.